GOLDMAN

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Retrieved on: 
星期四, 五月 9, 2024
FDA, Bone marrow, CRISPR, Research, Recode, IND, KLKB1, Medicine, Polyneuropathy, NK, AATD, Corporation, Congress, Brain, TTR, Amyloidosis, Food, Gene editing, Conference, Eye, Corporate social responsibility, BLA, HAE, Therapy, Safety, Tissue, Cystic fibrosis, Cardiomyopathy, ATM, DNA, Intellia Therapeutics, Bank, EAACI, Lung, AAT, Social, ATTR, NTLA, Cell, Disease, Regeneron Pharmaceuticals, Patient, Liver, ESG, Pharmaceutical industry

“Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-dose CRISPR-based therapies.

Key Points: 
  • “Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-dose CRISPR-based therapies.
  • Additionally, Intellia plans to report topline results from the Phase 2 portion in mid-2024 and present full results at a medical meeting in the second half of 2024.
  • Collaboration Revenue: Collaboration revenue was $28.9 million during the first quarter of 2024, compared to $12.6 million during the first quarter of 2023.
  • Net Loss: Net loss was $107.4 million for the first quarter of 2024, compared to $103.1 million during the first quarter of 2023.

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
星期二, 五月 7, 2024
FDA, Amyloid beta, Part, Total, PIPE, CDER, Transferrin receptor, Nerve, BBB, CSF, Biomarker, Gamma, Enzyme replacement therapy, Traffic barrier, Hunting, OTV, PTV, Food, MGH, IDS, Conference, MAPT, ALS, Therapy, Cerebrospinal fluid, SAN, MPS II, Hospital, Safety, AFL, SGSH, UC, Alpha-synuclein, LUMA, SNCA, Clinical trial, Glycogen storage disease, Neurodegenerative disease, MPS, COMPASS, Patient, Alfa, Acquisition, ETV, ATV, Hunter syndrome, Sanofi, Massachusetts General Hospital, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.
  • Total research and development expenses were $107.0 million for the quarter ended March 31, 2024, compared to $128.8 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $25.2 million for the quarter ended March 31, 2024, compared to $27.1 million for the quarter ended March 31, 2023.

Uniti Group Inc. to Participate at the Goldman Sachs 9th Annual Leveraged Finance and Credit Conference

Retrieved on: 
星期二, 五月 7, 2024
Treasury, UNIT, Conference, Event, ROCK

LITTLE ROCK, Ark., May 07, 2024 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its President and Chief Executive Officer, Kenny Gunderman, and Vice President, Investor Relations & Treasury, Bill DiTullio, are scheduled to participate at the Goldman Sachs 9th Annual Leveraged Finance and Credit Conference on May 14, 2024 in Rancho Palos Verdes, CA.

Key Points: 
  • LITTLE ROCK, Ark., May 07, 2024 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its President and Chief Executive Officer, Kenny Gunderman, and Vice President, Investor Relations & Treasury, Bill DiTullio, are scheduled to participate at the Goldman Sachs 9th Annual Leveraged Finance and Credit Conference on May 14, 2024 in Rancho Palos Verdes, CA.
  • Any investor materials will be made available on Uniti’s Investor Relations website at investor.uniti.com under the Events & Presentations tab.

Uranium Sector Expected to See a Run as Positive Momentum and Demand Builds

Retrieved on: 
星期二, 五月 7, 2024
Electronic document, STUD, Uranium, News, URL, Webcast, Radioactive decay, Knowledge, URG, Web browser, Forum, Probability, Cameco, FMC, Annual report, Stallion, TSX, Attention, Nuclear energy, Energy, Goldman Sachs, Energy & Fuels, System, Carbon, ANT, REUTERS, Marketing, G7, Miner, OTCQB, PALM, Encore, Anomaly, Mining, HMS, Q&A, Uranium mining

With the headlines and positive momentum in nuclear more generally, hedge funds and other commodity investors are back in the (uranium) sector.

Key Points: 
  • With the headlines and positive momentum in nuclear more generally, hedge funds and other commodity investors are back in the (uranium) sector.
  • A lot of it is done via physical funds, the easiest way to get exposure to uranium prices,” said Bram Vanderelst at trading firm Curzon Uranium.
  • And now, within our 2024 objectives, we remain focused on commencing production at the Alta Mesa Uranium Central Processing Plant.
  • "Energy Fuels maintained our momentum from 2023, by reporting continued profitability in Q1-2024, driven mainly by uranium.

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Retrieved on: 
星期一, 五月 6, 2024
FDA, Brain, BRAF V600, Day One, Investment, Food, Research, Insurance, Conference, U.S. FDA, MEK, Prescription, ASCO, BRAF, Patient, Society, Clinical trial, Annual general meeting, Food and Drug Administration, Ageing, Pharmaceutical industry

BRISBANE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2024 financial results and highlighted recent corporate achievements.

Key Points: 
  • Results from the FIRELIGHT-1 Phase 1b and next steps are expected in the second half of 2024.
  • Based on Day One’s current operating plan, management believes it has sufficient capital resources to fund anticipated operations into 2026.
  • R&D Expenses: Research and development expenses were $40.2 million for the first quarter of 2024 compared to $27.8 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $26.6 million for the first quarter of 2024 compared to $18.0 million for the first quarter of 2023.

Regeneron Announces Investor Conference Presentations

Retrieved on: 
星期一, 五月 6, 2024
Regeneron Pharmaceuticals, Conference, Pet industry

TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Key Points: 
  • TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
    RBC Capital Markets Global Healthcare Conference at 9:00 a.m.
  • ET on Tuesday, May 14, 2024
    Jefferies Global Healthcare Conference at 8:30 a.m.
  • ET on Wednesday, June 5, 2024
    Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m.
  • ET on Tuesday, June 11, 2024
    The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations .

Sana Biotechnology to Present at May and June 2024 Investor Conferences

Retrieved on: 
星期一, 五月 6, 2024
Bank of America, BofA Securities, Citizenship, Biotechnology, Patient, Conference

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June.

Key Points: 
  • SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June.
  • Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m.
  • Sana will present at the BofA Securities 2024 Healthcare Conference at 3:00 p.m. PT on Tuesday, May 14, 2024.
  • Sana will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 2:40 p.m.

Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
星期三, 五月 8, 2024
Other Health, Research, General Health, Professional Services, Pharmaceutical, Other Professional Services, Public Relations, Investor Relations, Science, Biotechnology, Communications, Other Science, Health, JNJ, Johnson & Johnson, Conference, Webcast, Eastern Time Zone

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.
  • Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, Executive Vice President, Innovative Medicine R&D will represent the Company in a session scheduled at 2:00 pm (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240508472086/en/

Emerald to Participate in Goldman Sachs’ Ninth Annual Leveraged Finance and Credit Conference

Retrieved on: 
星期三, 五月 8, 2024
Digital Marketing, Data Analytics, Marketing, Content Marketing, Advertising, Communications, Professional Services, Business, Emerald, Goldman Sachs, Commerce, Conference, Security (finance)

Emerald Holding, Inc. (NYSE: EEX) (“Emerald” or the “Company”), America’s largest producer of trade shows and their associated conferences, content and commerce, today announced that the Company is scheduled to participate in Goldman Sachs’ Ninth Annual Leveraged Finance and Credit Conference on May 14-15, 2024 in Rancho Palos Verdes, CA.

Key Points: 
  • Emerald Holding, Inc. (NYSE: EEX) (“Emerald” or the “Company”), America’s largest producer of trade shows and their associated conferences, content and commerce, today announced that the Company is scheduled to participate in Goldman Sachs’ Ninth Annual Leveraged Finance and Credit Conference on May 14-15, 2024 in Rancho Palos Verdes, CA.
  • The Company will participate in one-on-one investor meetings.
  • To request a meeting with management, please contact your Goldman Sachs representative.

Blackstone Appoints Philip Sherrill as Global Head of Insurance

Retrieved on: 
星期二, 五月 7, 2024
Asset Management, Professional Services, Insurance, Finance, Goldman Sachs, Blackstone Credit, Harvard College, Social studies, BX, Financial adviser

Blackstone (NYSE:BX) today announced the appointment of Philip Sherrill as Global Head of Insurance.

Key Points: 
  • Blackstone (NYSE:BX) today announced the appointment of Philip Sherrill as Global Head of Insurance.
  • In his new role, Mr. Sherrill will focus on growing the firm’s insurance platform globally, working closely with Gilles Dellaert, Global Head of Blackstone Credit & Insurance.
  • Blackstone’s insurance platform has tripled in size since 2020, recently surpassing $200 billion in assets under management.
  • Gilles Dellaert, Global Head of Blackstone Credit & Insurance, said: “We are very pleased to welcome Phil to Blackstone as Global Head of Insurance.